Previous 10 | Next 10 |
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) gained 40.1% last month, according to numbers from S&P Global Market Intelligence . The move, largely driven by an update on a key clinical trial, reverses a downtrend that had been underway since February. Iovance Biother...
SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent cli...
DiaMedica Therapeutics DMAC -27% after announcing mixed results for kidney disease therapy in mid-stage study.Celcuity CELC -18% after raises $56M capital via equity offering.Purple Innovation PRPL -12% after lowering Q2 guidance due to production challenge.ReSha...
Iovance Biotherapeutics (IOVA) drops 5.1% premarket after announcing clinical data for its tumor infiltrating lymphocyte ((TIL)) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC). The overall response rate ((ORR)) was 21.4% (n=28, one complete response a...
21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy First Patient Dosed in Registration-Supporting IOV-LUN-202 Study in Second Line mNSCLC ...
REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers,...
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down over 50% from their January highs. In May, the company disclosed it would be delaying its Biologic License Application (BLA) filing with the U.S. Food and Drug Administration (FDA) on its key drug until the first ha...
The following slide deck was published by Iovance Biotherapeutics, Inc. in conjunction with this event. For further details see: Iovanve Biotherapeutics (IOVA) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Iovance Biotherapeutics (IOVA) announces updated clinical data for lifileucel from Cohort 2 in the C-144-01 clinical study in patients with advanced melanoma. Median duration of response ((DOR)) was not reached at 33.1 months of median study follow up (range: 2.2 to 38.5+ months) and Overall ...
Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit ASCO Update Conference Call and Webcast at 12 p.m. ET...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...